Miracor Medical Systems appoints international scientific advisory council

184

Miracor Medical Systems has appointed an international scientific advisory council consisting of leading clinicians to support the further clinical and technological progress of its PiCSO acute myocardial infarction impulse system. The board includes Gregg W Stone (professor of Medicine Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital, New York, USA ; co-director of Medical Research and Education at the Cardiovascular Research Foundation in New York, USA).

The other members of the board include: Adrian P Banning (professor of Interventional Cardiology and consultant cardiologist, John Radcliffe Hospital, Oxford, UK); Malte Kelm (professor and chair of the Division of Cardiology, Pulmonary Diseases, and Vascular Medicine, University Hospital Düsseldorf, Düsseldorf, Germany) ; Werner Mohl (inventor of the PiCSO concept, professor and academic surgeon, Medical University of Vienna, Vienna, Austria); Tienush Rassaf (Heisenberg professor for Myocardial Infarction of the German Research Foundation at the Heinrich-Heine-University Düsseldorf and director of Cath Labs of the Department of Cardiology at the University Hospital Düsseldorf, Düsseldorf, Germany); and Azfar G  Zaman (professor of Cardiology, consultant interventional cardiologist, and head of Coronary Intervention and director of the Cardiac Catheter Laboratories, Freeman Hospital and Newcastle University, Newcastle upon Tyne, UK).


Stone says: “Miracor has made significant progress in demonstrating the effectiveness of PiCSO AMI Therapy and its potential benefits in the treatment of patients with acute myocardial infarction. Emerging experience in Europe confirms that the integration of PiCSO acute myocardial infarction therapy in the existing treatment pathways of primary PCI is feasible. I look forward to being part of the efforts to further prove the clinical utility of PiCSO, and to supporting the company to make this therapy available in the USA.”


Recent clinical data from the Prepare RAMSES study, published in Eurointervention journal further demonstrated that PiCSO may significantly reduce infarct size and enhance myocardial recovery in patients presenting with acute ST-segment elevation myocardial infarction (STEMI).


The Miracor PiCSO (pressure-controlled intermittent coronary sinus occlusion) impulse system is designed to treat acute STEMI patients and Non-STEMI (NSTEMI) patients by improving myocardial perfusion in complement with PCI. It is applied during PCI and designed to intermittently block the coronary sinus, thereby increasing perfusion of the myocardium and reducing injury resulting from myocardial infarction.

 

 

(Visited 23 times, 1 visits today)